| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1047491561 |
| P356 | DOI | 10.1007/S00115-006-2063-5 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00115-006-2063-5 |
| P698 | PubMed publication ID | 16534644 |
| P2093 | author name string | P D Schellinger | |
| T Steiner | |||
| E Jüttler | |||
| M Köhrmann | |||
| H B Huttner | |||
| A Hug | |||
| P2860 | cites work | Warfarin reversal | Q24672566 |
| Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation | Q28165271 | ||
| Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage | Q28242554 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Use of factor IX complex in warfarin-related intracranial hemorrhage | Q28375864 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| Managing oral anticoagulant therapy | Q30649541 | ||
| Surgery in intracerebral hemorrhage. The uncertainty continues. | Q30938740 | ||
| Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study | Q31522746 | ||
| Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range | Q31828961 | ||
| How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? | Q31920536 | ||
| Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary | Q33330139 | ||
| A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoi | Q33588616 | ||
| Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage | Q33592133 | ||
| Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency | Q33739974 | ||
| Virus safety of prothrombin complex concentrates and factor IX concentrates | Q33739983 | ||
| Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk | Q34103947 | ||
| Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view | Q34268430 | ||
| Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial | Q34306677 | ||
| A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement | Q34351655 | ||
| Recombinant activated factor VII for acute intracerebral hemorrhage. | Q34397275 | ||
| Ultra-early hemostatic therapy for intracerebral hemorrhage | Q35038228 | ||
| Risks of transfusion-transmitted infections: 2003. | Q35561964 | ||
| Anaphylactic transfusion reactions | Q35561967 | ||
| Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage | Q36256080 | ||
| Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population | Q38487466 | ||
| Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. | Q40447131 | ||
| Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. | Q40458214 | ||
| Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. | Q40519948 | ||
| Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors | Q40528209 | ||
| Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation | Q41047881 | ||
| Risk factors for intracranial hemorrhage in outpatients taking warfarin | Q42285556 | ||
| Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group | Q42287205 | ||
| Emergency reversal of anticoagulation after intracerebral hemorrhage | Q43574102 | ||
| Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage | Q43660765 | ||
| Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study | Q43787550 | ||
| Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation | Q43868121 | ||
| Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. | Q44182924 | ||
| Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate | Q44234275 | ||
| Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment | Q44439243 | ||
| Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects | Q44507049 | ||
| The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage | Q44865336 | ||
| Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people | Q45063600 | ||
| Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage | Q45081496 | ||
| Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis | Q45152382 | ||
| Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. | Q45184495 | ||
| Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial | Q45258336 | ||
| The Risk of Subarachnoid and Intracerebral Hemorrhages in Blacks as Compared with Whites | Q46388332 | ||
| Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial | Q47622762 | ||
| Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? | Q47834401 | ||
| Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups | Q48090061 | ||
| MRI evidence of past cerebral microbleeds in a healthy elderly population | Q48248966 | ||
| Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. | Q48456034 | ||
| The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. | Q48477002 | ||
| Predisposing factors to enlargement of spontaneous intracerebral hematoma. | Q48576009 | ||
| Novel MMP inhibitor has potential for treatment of stroke. | Q48792876 | ||
| Early hemorrhage growth in patients with intracerebral hemorrhage. | Q48821770 | ||
| Treatment of intraventricular hemorrhage with urokinase : effects on 30-Day survival. | Q49081771 | ||
| Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. | Q50320624 | ||
| Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. | Q50758503 | ||
| Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. | Q51081226 | ||
| Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. | Q53331171 | ||
| Optimal oral anticoagulant therapy in patients with mechanical heart valves. | Q53374247 | ||
| Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. | Q53389030 | ||
| Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. | Q53973073 | ||
| Prediction of intracerebral hemorrhage survival | Q57746280 | ||
| Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex | Q59281308 | ||
| Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves | Q68302454 | ||
| Intracerebral hematomas during anticoagulant treatment | Q68784254 | ||
| Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment | Q70148611 | ||
| Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators | Q71016449 | ||
| Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy | Q71264573 | ||
| Risk factors for impaired outcome after spontaneous intracerebral hemorrhage | Q71569773 | ||
| Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course | Q71614861 | ||
| Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials | Q72030226 | ||
| Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment | Q72340096 | ||
| Relation between blood pressure and outcome in intracerebral hemorrhage | Q72486658 | ||
| Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality | Q72808879 | ||
| What causes intracerebral hemorrhage during warfarin therapy? | Q73147726 | ||
| Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage | Q73387446 | ||
| A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group | Q73951222 | ||
| Hydrocephalus is a determinant of early mortality in putaminal hemorrhage | Q74290154 | ||
| Management of oral anticoagulant-induced intracranial haemorrhage | Q74578256 | ||
| Guidelines on oral anticoagulation: third edition | Q74605668 | ||
| The overdosed patient and bleedings with oral anticoagulation | Q77748897 | ||
| The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. | Q77800200 | ||
| Practical guidelines for the clinical use of plasma | Q78370916 | ||
| [Spontaneous intracerebral hemorrhages] | Q80103475 | ||
| P433 | issue | 6 | |
| P921 | main subject | anticoagulant | Q215118 |
| P304 | page(s) | 671-2, 674-6, 678-81 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Der Nervenarzt | Q15446312 |
| P1476 | title | [Intracerebral hemorrhage related to anticoagulant therapy] | |
| P478 | volume | 77 |
Search more.